Safety and effectiveness of laparoscopic intratumoral resection facilitated by coagulation of giant hepatic hemangioma: a matched case-control study and literature review

Surg Endosc. 2022 Jul;36(7):5149-5159. doi: 10.1007/s00464-021-08891-3. Epub 2021 Nov 29.

Abstract

Background: To report the safety and effectiveness of laparoscopic intratumoral resection facilitated by coagulation (LIRC) compared with laparoscopic hepatectomy (LH) in treating giant hepatic hemangioma.

Methods: From 2017 to 2020, 19 consecutive patients with giant hepatic hemangioma (≥ 10 cm) received LIRC in one center. We selected a subgroup of 103 patients treated by LH in other four centers who well matched the 19 consecutive patients treated with LIRC, in a 1:1 fashion based on the tumor location, tumor size, and body mass index. Furthermore, the differences in technical success, operative time, operative blood loss, change of laboratory indexes, hospital stays, complication and clinical responds are compared between the two groups.

Results: Technical success was achieved in all 38 patients. Patients in the LIRC group had a relative shorter operative time (P < 0.001) and less operative blood loss (P = 0.003). The serum levels of C-reactive protein (CRP), total bilirubin (TBil), alanine aminotransferase (ALT), and aspartate transaminase (AST) were elevated significantly (P < 0.05) 1 day after the resection and returned to normal within 7 days in both groups; however, relatively lower serum levels of those indexes were observed in the LIRC group (P < 0.05). The total complication rate was relatively lower in the LIRC group compared with the LH group (P = 0.029). Patients in the LIRC group had shorter hospital stays than those in the LH group (P = 0.010). The clinical response was similar in the two groups.

Conclusions: LIRC is safe and effective for treating giant hepatic hemangioma.

Keywords: Coagulation; Giant hepatic hemangioma; Laparoscopic intratumoral resection; Matched case–control study.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Loss, Surgical
  • Case-Control Studies
  • Hemangioma* / surgery
  • Hepatectomy / adverse effects
  • Humans
  • Laparoscopy* / adverse effects
  • Liver Neoplasms* / pathology
  • Liver Neoplasms* / surgery
  • Operative Time
  • Retrospective Studies
  • Treatment Outcome